Scarica l'app Stockscreener
1.59
13.57%
0.19
Dopo l'orario di chiusura:
1.58
-0.01
-0.63%
Precedente Chiudi:
$1.40
Aprire:
$1.42
Volume 24 ore:
798.94K
Relative Volume:
0.63
Capitalizzazione di mercato:
$99.96M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.8933
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
-5.36%
1M Prestazione:
-1.85%
6M Prestazione:
+79.42%
1 anno Prestazione:
+64.90%
Intervallo 1D:
$1.32
$1.60
Intervallo di 1 settimana:
$1.32
$1.70
Portata 52W:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.59 | 88.01M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo
Using flow based indicators on Prelude Therapeutics Incorporated2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Taking on analysts’ expectations and winning: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges - MSN
Published on: 2025-11-16 22:10:23 - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Weekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
How to build a custom watchlist for Prelude Therapeutics IncorporatedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pattern recognition hints at Prelude Therapeutics Incorporated upsideSwing Trade & Advanced Technical Analysis Signals - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingBuy Signal & Weekly Breakout Watchlists - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanMarket Performance Report & Daily Stock Momentum Reports - newser.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Prelude Therapeutics Incorporated stock deliver shareholder valueTrade Exit Summary & AI Forecast for Swing Trade Picks - newser.com
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Published on: 2025-11-14 02:04:28 - newser.com
Prelude Therapeutics Advances Pipeline and Strengthens Financials - TipRanks
Transcript : Prelude Therapeutics Incorporated, Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
Can Prelude Therapeutics Incorporated stock maintain operating margins2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... By GuruFocus - Investing.com Canada
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights - GuruFocus
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness By Investing.com - Investing.com South Africa
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):